WallStreetZenWallStreetZen

NASDAQ: LTRN
Lantern Pharma Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their LTRN stock forecasts and price targets.

Forecast return on equity

Is LTRN forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.66%

Forecast return on assets

Is LTRN forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

LTRN revenue forecast

What is LTRN's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$3.9M
Avg 2 year Forecast
$14.6M
Avg 3 year Forecast
$33.8M

LTRN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
LTRN$5.77N/AN/A
KRON$1.03$4.25+312.62%Strong Buy
CELU$3.21N/AN/A
TSBX$2.71N/AN/A
HCWB$1.66N/AN/A

Lantern Pharma Stock Forecast FAQ

What is LTRN's revenue growth forecast for 2026-2028?

(NASDAQ: LTRN) Lantern Pharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.23%.

Lantern Pharma's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast LTRN's revenue for 2026 to be $41,891,164, with the lowest LTRN revenue forecast at $41,891,164, and the highest LTRN revenue forecast at $41,891,164. On average, 1 Wall Street analysts forecast LTRN's revenue for 2027 to be $156,823,330, with the lowest LTRN revenue forecast at $156,823,330, and the highest LTRN revenue forecast at $156,823,330.

In 2028, LTRN is forecast to generate $363,056,751 in revenue, with the lowest revenue forecast at $363,056,751 and the highest revenue forecast at $363,056,751.

If you're new to stock investing, here's how to buy Lantern Pharma stock.

What is LTRN's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: LTRN) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is LTRN's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: LTRN) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.